Notes from the Field: Anthrax on a Sheep Farm in Winter — Texas, December 2023–January 2024
Julie M. Thompson, Kelly Spencer, Melissa Maass, Susan Rollo, Cari A. Beesley, Chung K. Marston, Alex R. Hoffmaster, William A. Bower, Maribel Gallegos Candela, John R. Barr, Anne E. Boyer, Zachary P. Weiner, María E. Negrón, Erin Swaney, Briana O’Sullivan

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| Date | Event | Diagnostic test, sample or source (collection date), location performed | Result | Interpretation |
|---|---|---|---|---|
| Dec 24, 2023 | Lamb death, butchering |
|
|
|
| Dec 25, 2023 | Patient consumed cooked lamb meat |
|
|
|
| Jan 1, 2024 | Patient visited general practitioner |
|
|
|
| Cephalexin* 500 mg per os (by mouth) every 8 hrs prescribed | ||||
| Jan 4, 2024 | Patient developed blisters, edema, and eschar | CBC, blood (Jan 4), Hospital A | Eosinophils count 0 103/ | Low–normal |
| Patient visited Hospital A | Eosinophils percent 0.02% (Ref = 1.00%–5.00%) | Low | ||
| Swabs, serum, and blood cultures collected | Erythrocyte MCH 31.2 pg (Ref = 27.0–31.0) | Normal–high | ||
| Vancomycin† 1 g IV every 24 hrs prescribed | Erythrocyte MCHC 36.0 g/dL (Ref = 33.0–37.0) | Normal–high | ||
| Vancomycin† discontinued | Erythrocyte MCV 86.6 fL (Ref = 80.0–105.0) | Normal | ||
| Ciprofloxacin§ 400 mg IV every 8 hrs prescribed | Erythrocyte count 5.21 x 106/ | Normal | ||
| Clindamycin§ 600 mg IV every 8 hrs prescribed | Hematocrit 45.1% (Ref = 42.0%–52.0%) | Normal | ||
| Hemoglobin 16.3 g/dL (Ref = 14.0–16.0) | High | |||
| Leukocytes count 14.65 x 103/ | High | |||
| Lymphocytes count 0.43 103/ | Low | |||
| Monocytes count 0.39 103/ | Normal | |||
| Monocytes percent 7.36% (Ref = 1.70%–9.30%) | Normal | |||
| MPV 7.0 fL (Ref = 7.4–10.4) | Low | |||
| Neutrophils count 13.77 103/ | High | |||
| Neutrophils percent 94.01% (Ref = 42.00%–75.20%) | High | |||
| Platelet count 191 x 103/ | Normal | |||
| Jan 5, 2024 | Patient transferred to Hospital B |
|
|
|
| Swabs, serum, and blood collected | ||||
| Jan 6, 2024 | Ewe #1 death, hemorrhage from eyes and nose |
|
|
|
| Jan 8, 2024 |
| Culture, patient swab (Jan 5), Hospital B | No growth |
|
| Real-time PCR,¶ patient swab (Jan 6), TX DSHS | Positive |
| ||
| Jan 11, 2024 | Ewe #2 death, hemorrhage from eyes and nose | Culture, patient swab (Jan 6), TX DSHS | No growth |
|
| Jan 12, 2024 | Patient discharged | Real-time PCR,¶ patient swab (Jan 4), TX DSHS | Positive |
|
| Swabs collected from both ewes | Culture, patient swab (Jan 4), TX DSHS | No growth |
| |
| Jan 15, 2024 | Convalescent serum collected from patient | Culture, ewe #1 swab (Jan 12), TVMDL | No growth |
|
| Culture, ewe #2 swab (Jan 12), TVMDL | No growth |
| ||
| Jan 30, 2024 |
| ELISA,** serum (Jan 4), CDC | 0 |
|
| ELISA,** serum (Jan 15), CDC | 31.4 |
| ||
| Jan 31, 2024 |
| Mass spectrometry,†† serum (Jan 4), CDC | 11.9 ng/mL |
|
| Mass spectrometry,†† serum (Jan 15), CDC | Below limit of detection |
|
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBacillus and Francisella bacterial research · Yersinia bacterium, plague, ectoparasites research · Zoonotic diseases and public health
Anthrax is a rare but serious infectious zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. In North America, animal outbreaks typically occur during summer in hot, dry weather (1). Rare cases among humans usually follow direct contact with or processing of anthrax-infected animals or contanimated animal products such as hides, hair, or wool (1,2). In early 2024, an unusual case of confirmed cutaneous anthrax* acquired during the winter in a geographic region with enzootic anthrax occurred, and an investigation was undertaken. This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy.†
Investigation and Outcomes
On January 4, 2024, a male rancher aged 50–59 years was evaluated at hospital A for fever, leukocytosis, a black eschar on his right wrist, and extensive edema and blistered lesions on his right arm; he was febrile and had an elevated white blood cell count (Table); anthrax was suspected to be the etiology. Eleven days earlier, on December 24, 2023, he had butchered a lamb that had died suddenly on his ranch, located in a Texas county adjacent to a region with enzootic anthrax, known as the “Anthrax Triangle.”§ Before its death, the lamb was healthy and showed no sign of disease. Five persons reported exposure to the lamb. The patient and another person seasoned and cooked the meat; the well-cooked meat was then consumed at a meal with three other persons. Among these five persons, only the index patient exhibited symptoms consistent with cutaneous anthrax, and none experienced symptoms consistent with gastrointestinal anthrax.¶
The patient was initially seen by a general practitioner on January 1 and commenced a course of cephalexin for empiric treatment of soft tissue infection. Anthrax was not initially suspected as the etiology of his symptoms. After 3 days of empiric antibiotic therapy without response, the patient was evaluated at hospital A. A detailed clinical history and the patient’s clinical signs and symptoms raised the index of suspicion for anthrax, and wound swabs and blood were collected before initiation of antimicrobial monotherapy for presumed nonsystemic, cutaneous anthrax. The patient showed signs of systemic involvement and dual therapy for anthrax (ciprofloxacin and clindamycin) was initiated (3) the same day. The following morning, he was transferred to hospital B, a larger facility equipped for a more extensive evaluation of his severe edema and malaise. The Texas Department of State Health Services Laboratory performed real-time polymerase chain reaction (PCR) testing and culture from the patient’s wound swabs. Two wound swabs were positive for B. anthracis DNA** by real-time PCR; however, culture did not yield an organism consistent with B. anthracis. The patient recovered and was discharged after 1 week, on January 12.
The lamb was suspected to be the source of the patient’s illness and, in light of suspected anthrax, interviews were conducted with the patient and his family members. On January 6 and January 11, two ewes subsequently died on the farm with ocular and nasal hemorrhage. Nasal swabs were collected ≥12 hours after death and sent to the Texas A&M Veterinary Medical Diagnostic Laboratory for culture for B. anthracis. Test results from both animals were negative; however a high level of clinical and epidemiologic suspicion for anthrax remained. No other animal deaths occurred during the remaining winter season.
Paired sera from the patient were sent to CDC to measure anti-protective antigen (PA) antibodies and lethal factor (LF), a toxin produced by B. anthracis, using enzyme-linked immunosorbent assay (ELISA) and mass spectrometry, respectively. A more than fourfold increase in the concentration of anti-PA immunoglobulin G†† was noted between serum specimens collected 11 days apart, indicating exposure to B. anthracis. LF concentration was 11.9 ng/mL in the acute serum sample,§§ one of the highest LF levels ever measured in a patient with cutaneous anthrax at CDC or any other location (4). Cooked meat from the lamb was stored frozen for 2 weeks and sent to CDC for real-time PCR and culture. DNA extraction was performed on three separate sections of tissues; all were positive for B. anthracis by real-time PCR despite no culture growth.
Preliminary Conclusions and Actions
Nonculture testing through real-time PCR, ELISA, and mass spectrometry at CDC Laboratory Response Network sites was critical to confirming the diagnosis of anthrax considering of the unusual seasonality and inability to culture B. anthracis. Older evidence suggests that first-generation cephalosporins might be effective against B. anthracis (5) and might have prevented culture growth. However, treatment of naturally occurring B. anthracis with cephalosporins is contraindicated because of intrinsic resistance (3). This patient recovered only after receiving treatment with antimicrobials effective against anthrax (3).
The lack of culture growth from the two ewes could be attributed to factors including delayed sampling, handling, storing, or shipping swabs. B. anthracis DNA was detected in cooked meat from the lamb, and there was no culture evidence of viable bacteria from the meat. The infecting bacteria possibly were inactivated when the meat was cooked at high temperatures; however, there is no safe way to prepare meat for human consumption from an animal that has died of anthrax.
This outbreak occurred on a farm adjacent to the Anthrax Triangle in Texas and near the location of a 2019 human cutaneous anthrax case that was associated with an outbreak in animals, which included 25 culture-positive animal cases (2). In both the 2019 case and the current case, the patients reported direct skin exposure to animal carcasses, emphasizing the importance of avoiding processing carcasses of animals that unexpectedly die of unknown causes in this region regardless of the season. If animals must be moved, personal protective equipment should be worn. There was no clear history of routine vaccination against anthrax for this herd, or whether the remaining herd was vaccinated after the three animal deaths. Concerns about vaccine-associated adverse events among goats and horses were previously reported in this area (2), and routine animal vaccination remains essential in preventing anthrax in animals and subsequent spillover into humans (1).
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Shadomy SV, Smith TL. Zoonosis update. Anthrax. J Am Vet Med Assoc 2008;233:63–72. 10.2460/javma.233.1.6318593313 · doi ↗ · pubmed ↗
- 2Sidwa T, Salzer JS, Traxler R, Control and prevention of anthrax, Texas, USA, 2019. Emerg Infect Dis 2020;26:2815–24. 10.3201/eid 2612.20047033219643 PMC 7706973 · doi ↗ · pubmed ↗
- 3Bower WA, Yu Y, Person MK, CDC guidelines for the prevention and treatment of anthrax, 2023. MMWR Recomm Rep 2023;72(No. RR-6):1–47. 10.15585/mmwr.rr 7206 a 137963097 PMC 10651316 · doi ↗ · pubmed ↗
- 4Boyer AE, Quinn CP, Beesley CA, Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax. J Infect Dis 2011;204:1321–7. 10.1093/infdis/jir 54321908727 PMC 3182309 · doi ↗ · pubmed ↗
- 5Swartz MN. Recognition and management of anthrax—an update. N Engl J Med 2001;345:1621–6. 10.1056/NEJ Mra 01289211704686 · doi ↗ · pubmed ↗
